Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-03-05Clinical Trial Update: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly [Phase 2]
Phase 2 study sponsored by Bristol-Myers Squibb in Japanese patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythem…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) [Phase 1, Phase 2]
A Phase 1/2 trial of Tagraxofusp (SL-401) in chronic myelomonocytic leukemia and myelofibrosis has completed with results posted (January 20…
-
CLINICAL_TRIALS trial_result · 2024-12-30Clinical Trial Update: Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. [NA]
A completed pilot clinical trial evaluating a diagnostic score to differentiate myeloproliferative neoplasms, including essential thrombocyt…
-
CLINICAL_TRIALS trial_result · 2024-12-18Clinical Trial Update: Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation [Phase 2]
A Phase 2 study evaluating the combination of ruxolitinib and enasidenib in patients with accelerated- or blast-phase myeloproliferative neo…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-28Clinical Trial Update: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) [Phase 3]
Phase 3 MANIFEST-2 study of pelabresib (CPI-0610) in myelofibrosis has posted results as of Oct 28, 2024; the trial remains active but not r…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects [Phase 1]
This update reports the completion of a Phase 1 study evaluating the drug-drug interaction of pacritinib with cytochrome P450 substrates and…
-
CLINICAL_TRIALS trial_result · 2024-10-09Clinical Trial Update: Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors [Phase 2]
A Phase 2 trial of selinexor in patients with myelofibrosis refractory or intolerant to JAK1/2 inhibitors was terminated, with results poste…
-
CLINICAL_TRIALS trial_result · 2024-10-04Clinical Trial Update: To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) [Phase 3]
A Phase 3 trial (LIMBER-313) evaluating Parsaclisib in combination with Ruxolitinib for myelofibrosis was terminated, with results posted in…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) [Phase 2]
Phase 2 LIMBER-213 evaluated the safety, tolerability, and efficacy of Itacitinib immediate-release tablets in adults with primary or second…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) [Phase 3]
Phase 3 LIMBER-304 trial evaluating parsaclisib with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib was termi…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias [Phase 1, Phase 2]
An early-phase study of escalating doses of AT9283 for various leukemias has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea [Phase 1]
This Phase 1 trial evaluated the combination of TGR-1202 and ruxolitinib in patients with myelofibrosis and polycythemia vera who are resist…
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis [Phase 2]
Phase 2 study of INCB050465 in combination with ruxolitinib for myelofibrosis. The trial was terminated and results were posted in May 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of oral GB2064 in participants with myelofibr…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer [Phase 2]
Phase 2 study evaluating a conditioning regimen of fludarabine phosphate, cyclophosphamide, and total body irradiation followed by donor ste…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis [Phase 2]
A Phase 2 clinical trial investigating a JAK inhibitor given before donor stem cell transplantation in patients with primary or secondary my…
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Actuate 1901: 9-ING-41 in Myelofibrosis [Phase 2]
Phase 2 clinical trial update for 9-ING-41 in myelofibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial evaluating fedratinib versus best available therapy in high- or intermediate-risk myelofibrosis subtypes after ruxolitinib f…
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) [Phase 1, Phase 2]
Clinical trial update for Bomedemstat (IMG-7289/MK-3543) in myelofibrosis showing completion and posted results for Phase 1/2 study.
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Myeloproliferative Neoplasms: an In-depth Case-control Study
A completed clinical trial examining myeloproliferative neoplasms with results posted; focuses on Polycythemia Vera, Essential Thrombocythem…
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia [Phase 2]
A Phase 2 trial evaluating fostamatinib alone or with ruxolitinib for myelofibrosis patients with severe thrombocytopenia has been terminate…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis [Phase 3]
A Phase 3 trial comparing jaktinib to hydroxyurea in intermediate-2 or high-risk myelofibrosis has completed.